Semaglutide powder is a GLP-1 analog that has been approved by the FDA for the treatment of type 2 diabetes. It regulates blood sugar levels by stimulating insulin secretion and inhibiting glucagon secretion. In addition, semaglutide has also been widely studied for the treatment of other conditions, including:
1. Obesity: The mechanism of semaglutide related to weight loss has been well studied, and it has been approved by the FDA as a drug for the treatment of obesity.
2. Cardiovascular disease: The effects of semaglutide on the cardiovascular system have also been widely studied. A recent study found that long-term use of semaglutide can reduce the risk of cardiovascular events in patients with type 2 diabetes.
3. Alzheimer's disease: Semaglutide has also been studied for the treatment of Alzheimer's disease, and its glucagon pathway has a certain relationship with the occurrence of Alzheimer's disease, so semaglutide may have a positive effect on Alzheimer's disease Impact.
4. Liver fibrosis: Semaglutide may have therapeutic effects on liver fibrosis through multiple mechanisms, such as inhibiting the proliferation of insulin-like growth factor 1 (IGF-1), inhibiting the expression of α-smooth muscle actin (α-SMA) and promoting Release of gastrin-like peptide-2 (GLP-2) guides hepatocyte regeneration.
5. Studies have also found that Semaglutide can reduce the risk of cancer death in various types of systemic cancer treatment.
In short, Semaglutide has not only been approved by the FDA in the treatment of diabetes, but also has a wide range of therapeutic applications and research in other fields.
Peptide semaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes. The following is its synthetic route and detailed steps:
1. Synthesis of alanine derivatives: starting from mercaptoalanine, through carbonylation and reduction reactions, alanine derivatives were synthesized.
2. Synthesis of azide compounds: use the substrate N,N-dimethylacetamide and tetramethylammonium azide salt to prepare azide compounds through reaction.
3. Synthesis of peptides: react the alanine derivatives in step 1 with the azide compounds in step 2 to generate peptides.
4. Calcium-catalyzed cyclization: Add calcium salt catalyst to peptides in ethylene glycol for cyclization reaction to generate peptides containing 1,2,4-thiadiazole rings.
5. Acylation: The peptide undergoes acylation reaction to introduce hexadecanoyl to improve bioavailability.
6. Purification and mass spectrometry: The final step is to purify the peptide by reverse osmosis and high performance liquid chromatography, and confirm it by mass spectrometry.
Overall, the total synthesis scheme of semaglutide is highly optimized and efficient, and it was successful in high yield and good quality.
The polypeptide semaglutide is a long-acting GLP-1 receptor agonist. The polypeptide semaglutide contains 34 amino acid residues, the molecular formula is C187H291N45O59, and the relative molecular mass is 4110.86. It is a colorless solid that dissolves in water. The polypeptide molecule contains many hydrophilic groups, so it exhibits high hydrophilicity in solution. The physical and chemical properties of the polypeptide semaglutide determine that it needs special protection during its preparation, storage and use.
Development History:
The research and development history of peptide semaglutide can be traced back to the 1990s. Initially, the researchers aimed to create a direct injectable type 2 diabetes drug that would mimic the body's internal GLP-1 hormone. During the research, Semaglutide, as a highly effective GLP-1 receptor agonist, has shown good efficacy in animal models. After years of research and development, the peptide Semaglutide was successfully launched in 2021 and has become a widely used anti-diabetic drug.
Application prospects:
Peptide semaglutide, as a long-acting GLP-1 receptor agonist, has a good application prospect. It can be widely used in the treatment of patients with type 2 diabetes, and can lower blood sugar, improve insulin sensitivity, and reduce body weight. In addition, semaglutide can also be used to treat diseases such as obesity and cardiovascular disease. In the future, the application prospect of peptide semaglutide will be broader, and researchers are constantly studying its application in the fields of medicine and life sciences.
Semaglutide, which is approved for weight loss in obese or overweight adults, can also help teens lose weight and support heart health, according to new research. Published November 2, 2022 in the New England Journal of Medicine (NEJM), obese adolescents who received weekly semaglutide experienced a reduction in body mass index (BMI) in an international phase 3a clinical trial increased by 16.1%, compared with a 0.6% increase in the placebo group.
Semaglutide Semaglutide (Semaglutide) was developed by Novo Nordisk. The drug was originally used to treat diabetes. It is a glucagon-like peptide 1 (GLP-1) receptor agonist and can mimic its action. , reduce hunger, reduce diet, and reduce calorie intake, so it has an outstanding effect in weight loss.
In February 2021, the "New England Journal of Medicine" (NEJM) published the results of a global large-scale clinical trial showing that semaglutide has an outstanding effect as a weight loss drug. Compared with the placebo group, 2.4mg semaglutide was injected weekly The experimental group with marutide lost an average of 15.3 kg. Specifically, three-quarters of people lost more than 10% of their body weight, and more than one-third of people lost more than 20% of their body weight. This weight loss effect can be called "game-changing". Weight loss that can only be achieved through surgery.
Based on the success of this clinical trial, in June 2021, the US Food and Drug Administration (FDA) approved the marketing of semaglutide (Semaglutide) weight loss drug.